Patents Examined by Jacqueline Stone
  • Patent number: 5504005
    Abstract: Recombinant mycobacterial vaccine vehicles capable of expressing DNA of interest which encodes at least one protein antigen for at least one pathogen against which an immune response is desired and which can be incorporated into the mycobacteria or stably integrated into the mycobacterial genome. The vaccine vehicles are useful for administration to mammalian hosts for purposes of immunization. A recombinant vector which replicates in E. coli but not in mycobacteria is also disclosed. The recombinant vector includes 1) a mycobacterial gene or portions thereof, necessary for recombination with homologous sequences in the genome of mycobacteria transformed with the recombinant plasmid; 2) all or a portion of a gene which encodes a polypeptide or protein whose expression is desired in mycobacteria transformed with the recombinant plasmid; 3) DNA sequences necessary for replication and selection in E. coli; and 4) DNA sequences necessary for selection in mycobacteria (e.g., drug resistance).
    Type: Grant
    Filed: June 5, 1989
    Date of Patent: April 2, 1996
    Assignees: Albert Einstein College of Medicine of Yeshiva University, The Board of Trustees of the Leland Stanford, Jr. University, Whitehead Institute for Biomedical Research
    Inventors: Barry R. Bloom, Ronald W. Davis, William R. Jacobs, Jr., Richard A. Young, Robert N. Husson
  • Patent number: 5470726
    Abstract: Retrovirus packaging cell lines PG13 (ATCC No. CRL 10686) and PG13/LNc8 (ATCC No. CRL 10685), and retroviruses packaged by said cells.
    Type: Grant
    Filed: August 11, 1993
    Date of Patent: November 28, 1995
    Assignees: Fred Hutchinson Cancer Research Center, The United States of America as represented by the Department of Health and Human Services
    Inventors: A. Dusty Miller, Jose V. Garcia-Martinez, Maribeth V. Eiden, Carolyn A. Wilson
  • Patent number: 5470971
    Abstract: Genes (and portions thereof) which are stress-inducible, e.g., by cold-shock which encode useful proteins. The proteins contribute to confer thermo-tolerance and/or contribute to confer low temperature tolerance to organisms, like eucaryotes or procaryotes. Typical genes encoding such proteins and homologous genes encoding proteins with equivalent properties are discussed. Nucleotide sequences encoding such proteins, recombinant replicable expression vehicles which comprise DNA constructs which encode such proteins and competent transformed organisms like eucaryotes are discussed. The production of valuable fermentation products and of biologically active proteins under conditions outside the normal or optimum physiological growth conditions are described.
    Type: Grant
    Filed: March 11, 1991
    Date of Patent: November 28, 1995
    Assignee: The University of Medicine and Dentistry of New Jersey
    Inventors: Keiji Kondo, Masayori Inouye
  • Patent number: 5468726
    Abstract: The administration of Somatostatin and growth hormone releasing factor at useful dosage levels alleviates the symptoms of various neuropsychiatric disorders.Growth hormone and neuropsychiatric responses to the administration of growth hormone releasing factor to mammals indicate its usefulness as an antemortem marker for senile dementia of the Alzheimer's type.
    Type: Grant
    Filed: February 23, 1990
    Date of Patent: November 21, 1995
    Assignee: Ares Holding 89 N.V.
    Inventor: Ramon Cacabelos
  • Patent number: 5457037
    Abstract: The structural gene encoding isoamylase from Pseudomonas SMP 1 is obtained. Also described are vectors comprising the isoamylase gene and host microorganisms transformed by these vectors. The transformed host microorganisms are capable of expressing and/or secreting mature isoamylase having biological activity.
    Type: Grant
    Filed: January 8, 1993
    Date of Patent: October 10, 1995
    Assignee: Enichem Synthesis, S.p.A.
    Inventors: Angelo Tognoni, Paolo Carrera, Barbara Camerini, Giuliano Galli, Giuseppe Lucchese, Guido Grandi, Carlo Di Gennaro
  • Patent number: 5453366
    Abstract: An improved method of cloning mammalian embryos by transferring a nucleus from a donor mammalian embryo to an enucleated recipient oocyte and culturing the nuclear transferred bovine embryo in vitro is described. The improvement includes positioning the donor embryo nucleus adjacent to the enucleated recipient oocyte, and maintaining the nucleus and oocyte in a maintenance medium for a time sufficient to mature the cytoplasm of the enucleated recipient oocyte prior to fusing the donor nucleus to the recipient oocyte.
    Type: Grant
    Filed: March 15, 1993
    Date of Patent: September 26, 1995
    Inventors: Michele M. Sims, Charles F. Rosenkrans, Jr.
  • Patent number: 5445954
    Abstract: Discoveries are disclosed that show that certain mutations in different parts of the mechanism for regulation of independently replicating element replication can be combined in one expression independently replicating element to produce a runaway-replication phenotype that is suppressible by a diffusible factor from another independently replicating element co-resident in the host cell. According to the present invention, an expression independently replicating element combining known inducible promoters with this runaway-replication phenotype is used in combination with a independently replicating element that suppresses this runaway phenotype to establish a gene expression system that provides both controllable gene amplification and controllable induction of gene expression without the use of chemical inducers or temperature shifts. This expression system produces high yields of proteins in readily isolatable forms.
    Type: Grant
    Filed: February 11, 1993
    Date of Patent: August 29, 1995
    Assignee: The Johns Hopkins University
    Inventors: Ru C. Huang, Paul E. Giza
  • Patent number: 5436330
    Abstract: A DNA fragment is disclosed which has connected to the downstream side of a first DNA sequence containing a region coding for the first ribozyme RNA a second DNA sequence containing a region coding for second ribozyme RNA capable of cleaving by self-processing the 3'-terminus site of the first ribozyme RNA subjected to transcription. A ribozyme having the 3'-terminus site thereof self-processed is obtained by effecting transcription of a RNA using as a template a recombinant vector obtained by recombination by the use of the DNA fragment.
    Type: Grant
    Filed: August 24, 1993
    Date of Patent: July 25, 1995
    Assignees: Agency of Industrial Science & Technology, Ministry of International Trade & Industry
    Inventors: Kazunari Taira, Masanao Oda, Hideaki Shinshi, Kensuke Furukawa, Hidekatsu Maeda
  • Patent number: 5433955
    Abstract: A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.
    Type: Grant
    Filed: October 8, 1993
    Date of Patent: July 18, 1995
    Assignee: Akzo N.V.
    Inventors: Reinhard Bredehorst, Chong-Ho Kim, Richard McCabe, Nicholas Pomato, Carl-Wilhelm Vogel
  • Patent number: 5427918
    Abstract: Oxidized derivatives of-fibrin and fibrin or fibrinogen degradation products or partial sequences, process for their preparation and their use as medicaments, for diagnosis or as an affinity agent are described.
    Type: Grant
    Filed: January 19, 1993
    Date of Patent: June 27, 1995
    Assignee: Behringwerke Aktiengesellschaft
    Inventor: Thomas Stief
  • Patent number: 5425940
    Abstract: Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
    Type: Grant
    Filed: February 3, 1994
    Date of Patent: June 20, 1995
    Assignee: Cetus Oncology Corporation
    Inventors: Robert Zimmerman, Jeffrey L. Winkelhake
  • Patent number: 5424197
    Abstract: An H. saimiri-HTLV-1 or 2 X region vector is disclosed. This vector can be used to establish continuous cell lines of difficult to grow cells, such as human T-cells. It can also be used to obtain certain cell products and in methods for screening new compounds.
    Type: Grant
    Filed: November 16, 1992
    Date of Patent: June 13, 1995
    Assignees: Dana Farber Cancer Institute, Behringwerke Aktiengesellschaft
    Inventors: William A. Haseltine, Kathleen McGuire, Marie-Christine Dokhelar, Ralph Grassmann, Bernard Fleckenstein, Ingrid Muller-Fleckenstein
  • Patent number: 5422249
    Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.
    Type: Grant
    Filed: September 15, 1993
    Date of Patent: June 6, 1995
    Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AG
    Inventors: Manfred Liersch, Hans Rink, Walter Marki, Markus G. Grutter, Bernd Meyhack
  • Patent number: 5419906
    Abstract: The effects of Cohn-Oncley cold alcohol fractionation on infectivity of two prototype retroviruses, mouse xenotropic type C and the LAV strain of AIDS retrovirus result in a significant reduction in retrovirus titer. At least a 100,000-fold reduction of LAV was obtained when fractionating plasma to fraction II. Adjustment to pH 4.0 at filtrate III was as effective for viral inactivation as was precipitation of fraction II from filtrate III with 25% ethanol. Liquid immunoglobulin preparations spiked with LAV and incubated at 27.degree. C. for 3 days resulted in an additional 1,000-10,000-fold reduction of LAV titer. Our results support the clinical and epidemiological evidence that therapeutic immunoglobulin preparations prepared by Cohn-Oncley cold ethanol processing (at least about 18% v/v alcohol, pH.ltoreq.5.4) and then stored at a pH equal to or less than about 5.4 and a temperature of at least 27.degree. C. for at least 3 days, do not transmit retroviruses such as the LAV strain of the AIDS virus.
    Type: Grant
    Filed: October 23, 1992
    Date of Patent: May 30, 1995
    Assignee: Miles Inc.
    Inventors: Gautam Mitra, Milton M. Mozen, Robert E. Louie
  • Patent number: 5419901
    Abstract: Reducing plasma levels of endogenous arginine by parenteral administration of arginine depleting agent reduces nitric oxide levels and results in blood pressure increase. Preferably arginase is administered intravenously to raise blood pressure. The arginase can be administered in conjunction with arginine antagonists to potentiate the effect of these. Duration of action and avoidance of antigenicity may be obtained by use in conjunction with a carrier or modifier.
    Type: Grant
    Filed: February 22, 1993
    Date of Patent: May 30, 1995
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Owen W. Griffith
  • Patent number: 5420026
    Abstract: The invention pertains to self-assembled replication defective hybrid virus-like particles having capsid and membrane glycoproteins from at least two different virus types and method of making same. Recombinant viral vectors as well as the viral particles can be used as immunogens and drug delivery vehicles.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: May 30, 1995
    Assignee: Therion Biologics Corporation
    Inventor: Lendon Payne
  • Patent number: 5418164
    Abstract: An agent for combating pests and for protecting plants comprising a carrier-free cell granulate of a microorganism which is suitable for combating pests or for plant treatment such as fungi or bacteria which are capable of mycelium formation, e.g. Deuteromycetes and Metarhizium including the new anisopliae strains DMS 3884 and 3885.
    Type: Grant
    Filed: April 5, 1993
    Date of Patent: May 23, 1995
    Assignee: Bayer Aktiengesellschaft
    Inventors: Wolfram Andersch, Jurgen Hartwig, Bernhard Homeyer, Klaus Stenzel
  • Patent number: 5416021
    Abstract: The present invention relates to new recombinant DNA-molecules comprising nucleotide sequences of S. dysgalactiae encoding for at least one protein or polypeptide having fibronectin binding property.
    Type: Grant
    Filed: September 23, 1993
    Date of Patent: May 16, 1995
    Assignee: Alfa-Laval Agri International Aktiebolag
    Inventors: Magnus Hook, Kjell M. Lindberg, Per-Eric Lindgren, Lars C. Signas
  • Patent number: 5413927
    Abstract: Disclosed is an isolated and purified feline immunodeficiency virus (FIV) culture having the identifying characteristics of FIV isolate NCSU.sub.1. A biologically pure culture of host cells containing a FIV having the identifying characteristics of FIV isolate NCSU.sub.1 is also disclosed, along with isolated and purified DNA coding for (a) an FIV having the identifying characteristics of FIV isolate NCSU.sub.1, or (b) an antigenic fragment of an FIV having the identifying characteristics of FIV isolate NCSU.sub.1. Various vaccine formulations containing active agents derived from the foregoing FIV virus, DNA encoding the virus, and DNA encoding antigenic fragments of the virus are also disclosed herein.Also disclosed are immunodeficient mice containing feline tissue, which feline tissue is capable of infection with a feline immunodeficiency virus such as (but not limited to) FIV isolate NCSU.sub.1.
    Type: Grant
    Filed: August 12, 1993
    Date of Patent: May 9, 1995
    Assignee: North Carolina State University
    Inventors: Wayne A. F. Tompkins, Mary B. Tompkins
  • Patent number: 5413784
    Abstract: The subject invention concerns a novel anal useful biopesticide with activity against insect pests such as boll weevil, sweet potato whitefly and cotton fleahopper. The biopesticide of the subject invention comprises an entomopathogenic fungus having virulence against a targeted insect pest(s), an arrestant anal feeding stimulant for the targeted insect pest(s) anal, optionally, a pheromone for the targeted insect pest(s). A preferred fungus is a Beauveria bassiana, preferably Beauveria bassiana, ATCC-74040 (ARSEF-3097). By using this novel fungus, or mutant thereof, in the composition of the present invention, Boll weevils, sweet potato whiteflies anal cotton fleahoppers can be controlled without environmental and public safety hazards presented by chemical control agents.
    Type: Grant
    Filed: May 10, 1993
    Date of Patent: May 9, 1995
    Inventors: James E. Wright, Laurence D. Chandler